NICE gives go-ahead for Lucentis

The National Institute for Health and Clinical Excellence has said primary care trusts should fund the use of ranibizumab - commonly known as Lucentis - for the treatment of wet age-related macular degeneration if certain conditions apply.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here